Related Experiment Video
Updated: Mar 1, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.6K
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
Eva S Laube1, Anthony Yu2, Dipti Gupta2
1Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
The American Journal of Cardiology
|May 28, 2017
Summary
Rivaroxaban is safe and effective for preventing stroke in patients with nonvalvular atrial fibrillation (AF) and active cancer. Its safety and efficacy in this population are comparable to those in the general population.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Rivaroxaban is widely used for stroke prevention in nonvalvular atrial fibrillation (AF).
- Limited evidence exists on rivaroxaban's safety and efficacy in patients with active cancer and AF.
Purpose of the Study:
- To assess the safety and efficacy of rivaroxaban for AF in patients with active cancer.
Main Methods:
- Retrospective analysis of 163 patients with active cancer and AF treated with rivaroxaban (Jan 2014-Mar 2016).
- Clinical endpoints assessed via medical record text searches.
- Adjusted for competing risks.
Main Results:
- 1-year cumulative incidence of ischemic stroke: 1.4% (95% CI 0% to 3.4%).
- 1-year cumulative incidence of major bleeding: 1.2% (95% CI 0% to 2.9%).
- 1-year cumulative incidence of nonmajor bleeding leading to discontinuation: 14.0% (95% CI 4.2% to 22.7%).
- 1-year cumulative incidence of mortality: 22.6% (95% CI 12.2% to 31.7%).
Conclusions:
- Rivaroxaban treatment for nonvalvular AF in patients with active cancer demonstrates comparable safety and efficacy to the general population.
- Results align with findings from the ROCKET-AF trial.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
425
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
425
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:30Venous Thrombosis IV: Nursing Management
324
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
324
02:49Cancer Therapies
10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K